Ultragenyx Pharmaceutical (RARE) Enterprise Value (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Enterprise Value for 14 consecutive years, with -$406.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 16.7% year-over-year to -$406.0 million; the TTM figure through Mar 2026 stood at -$406.0 million (up 16.7% YoY), while the FY2025 annual figure was -$673.0 million, down 11.61% from the prior year.
• Enterprise Value advanced to -$406.0 million in Q1 2026 per RARE's latest filing, from -$673.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$135.8 million in Q4 2022 and bottomed at -$888.7 million in Q3 2022.
• Historically, Enterprise Value has averaged -$521.5 million across 5 years, with a median of -$542.8 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 58.37% — and 2024, when it slumped 177.62%.
• Ultragenyx Pharmaceutical's Enterprise Value stood at -$135.8 million in 2022, then sank by 60.0% to -$217.2 million in 2023, then plunged by 177.62% to -$603.0 million in 2024, then decreased by 11.61% to -$673.0 million in 2025, then surged by 39.67% to -$406.0 million in 2026.
• Business Quant data shows RARE's Enterprise Value at -$406.0 million in Q1 2026, -$673.0 million in Q4 2025, and -$418.2 million in Q3 2025.